Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells.
Yuting Ma,Sandy Adjemian,Stephen R. Mattarollo,Takahiro Yamazaki,Laetitia Aymeric,Heng Yang,Joao Paulo Portela Catani,Dalil Hannani,Helene Duret,Kim Steegh,Isabelle Martins,Frederic Schlemmer,Mickael Michaud,Oliver Kepp,Abdul Qader Sukkurwala,Laurie Menger,Erika Vacchelli,Nathalie Droin,Lorenzo Galluzzi,Roman Krzysiek,Siamon Gordon,Philip R. Taylor,Peter Van Endert,Eric Solary,Mark J. Smyth,Laurence Zitvogel,Guido Kroemer
DOI: https://doi.org/10.1016/j.immuni.2013.03.003
IF: 32.4
2013-01-01
Immunity
Abstract:The therapeutic efficacy of anthracyclines relies on antitumor immune responses elicited by dying cancer cells. How chemotherapy-induced cell death leads to efficient antigen presentation to T cells, however, remains a conundrum. We found that intra-tumoral CD11c(+)CD11b(+)Ly6C(hi) cells, which displayed some characteristics of inflammatory dendritic cells and included granulomonocytic precursors, were crucial for anthracycline-induced anticancer immune responses. ATP released by dying cancer cells recruited myeloid cells into tumors and stimulated the local differentiation of CD11c(+)CD11b(+)Ly6C(hi) cells. Such cells efficiently engulfed tumor antigens in situ and presented them to T lymphocytes, thus vaccinating mice, upon adoptive transfer, against a challenge with cancer cells. Manipulations preventing tumor infiltration by CD11c(+)CD11b(+)Ly6C(hi) cells, such as the local overexpression of ectonucleotidases, the blockade of purinergic receptors, or the neutralization of CD11b, abolished the immune system-dependent antitumor activity of anthracyclines. Our results identify a subset of tumor-infiltrating leukocytes as therapy-relevant antigen-presenting cells.